Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) rose 6.9% on Thursday . The company traded as high as $23.02 and last traded at $23.00, with a volume of 120,252 shares. The stock had previously closed at $21.52.

ENTA has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 12th. Vetr downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price on the stock. in a report on Monday, April 25th. Finally, JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Enanta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $28.58.

The company has a 50-day moving average price of $23.12 and a 200-day moving average price of $26.56. The stock has a market capitalization of $430.89 million and a PE ratio of 13.36.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by $0.19. During the same quarter last year, the firm posted $1.49 earnings per share. The business had revenue of $13 million for the quarter, compared to analyst estimates of $16.80 million. The firm’s quarterly revenue was down 77.4% on a year-over-year basis. Equities analysts predict that Enanta Pharmaceuticals Inc. will post $1.00 earnings per share for the current year.

Other institutional investors recently bought and sold shares of the company. Schroder Investment Management Group increased its position in Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock valued at $14,506,000 after buying an additional 210,303 shares during the last quarter. Matarin Capital Management LLC bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $4,644,000. First Trust Advisors LP bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $1,374,000. EQIS Capital Management increased its position in Enanta Pharmaceuticals by 382.0% in the fourth quarter. EQIS Capital Management now owns 44,836 shares of the company’s stock valued at $1,480,000 after buying an additional 35,534 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock valued at $2,652,000 after buying an additional 24,670 shares during the last quarter.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.